Skip to main content

Table 7 Innate immune cells for cancer immunotherapy

From: Combination strategies to maximize the benefits of cancer immunotherapy

Natural killer cells

Stimulatory

Activating receptors: NKP30, NKP44, NKG2D, CD16, 2B4

Cytokines: IL-2 and IL-15

Engineered NK cells

Inhibitory

ITIM-containing receptors (KIR family, PD1 and TIGIT)

CD94/NKG2A

LIR1

TIM-3

IDO

Dendritic cells

Stimulatory

cGAS-STING pathway

TLR

Cytokines: GM-CSF, Type I IFN, FLT3L

Inhibitory

ITIM-containing receptors (FcγRIIB, etc.)

CD39/CD73/adenosine pathway

IDO

Macrophages

Stimulatory

CpG oligonucleotide

IFN-γ

TNF-α

IL-12

TLR agonists

Inhibitory

ITIM-containing receptors (SIRPα-CD47, SIGLEC-10, etc.)

IL-10, IL-4, IL-13

CCL5, CCL2/CCR2